scholarly journals Case Report of a Patient with Continuous Neuropathic Pain on the Maxillary Alveolar Area. Atypical Odontalgia.

1999 ◽  
Vol 43 (6) ◽  
pp. 970-976
Author(s):  
Takuo Kuboki ◽  
Mami Inoue ◽  
Katsushi Furuno ◽  
Yoshizo Matsuka ◽  
Kenji Maekawa ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Atypical Odontalgia ◽  
Alveolar Area

Intramuscular Injection of Ketamine in the Treatment of Postburn Neuropathic Pain -A case report-

2004 ◽  
Vol 17 (2) ◽  
pp. 248
Author(s):  
Chul Ho Woo ◽  
Sung Ha Mun ◽  
Soo Yeon Lee ◽  
Tae Hyung Han ◽  
Hyun Soo Kim ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Intramuscular Injection

scholarly journals Cognitive–Evaluative Dimension of Pain in Neuropathic Pain Relapse in Sciatica: A Case Report

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 658
Author(s):  
Tsubasa Kawasaki ◽  
Takuya Yada ◽  
Masahiro Ohira
Keyword(s):  
Neuropathic Pain ◽  
Low Back Pain ◽  
Back Pain ◽  
Case Report ◽  
Acute Phase ◽  
Low Back ◽  
Evaluative Dimension ◽  
Long Duration ◽  
Improvement Process ◽  
Insight Into

The cognitive–evaluative (C–E) dimension of pain is commonly observed in patients with a relatively long duration of pain. However, little is known about the effects of pain relapse on the C–E dimension of pain. Moreover, the improvement process of the C–E dimension of pain following treatment is unknown. The objective of this case report was to (a) demonstrate that the C–E dimension was affected in the acute phase of neuropathic pain in cases of pain relapse, and (b) demonstrate the improvement process of the C–E dimension of pain. A woman was diagnosed with low back pain (LBP) and sciatica. The patient had previously experienced symptoms of LBP and sciatica; thus, this episode was a case of pain relapse. At the beginning of rehabilitation, the C–E dimension of pain was present in addition to the sensory–discriminative (S–D) dimension of pain. It was observed that improvement of the C–E dimension of pain was delayed in comparison with that of the S–D dimension of pain. The C–E dimension of pain was observed with pain relapse even though it was in the acute phase of pain. This case provides a novel insight into the C–E dimension of pain. Moreover, the delay in improving the C–E dimension of pain indicates a difference in the improvement process for each pain dimension.

scholarly journals Neuropathic pain post-COVID-19: a case report

2021 ◽  
Vol 14 (7) ◽  
pp. e243459
Author(s):  
Matthew McWilliam ◽  
Michael Samuel ◽  
Fadi Hasan Alkufri
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Hospital Admission ◽  
Skin Biopsy ◽  
Neurological Examination ◽  
Autonomic Failure ◽  
Whole Body ◽  
Shortness Of Breath ◽  
Burning Pain ◽  
Electrophysiological Tests

A 61-year-old man with no significant medical history developed fever, headache and mild shortness of breath. He tested positive for SARS-CoV-2 and self-isolated at home, not requiring hospital admission. One week after testing positive, he developed acute severe burning pain affecting his whole body, subsequently localised distally in the limbs. There was no ataxia or autonomic failure. Neurological examination was unremarkable. Electrophysiological tests were unremarkable. Skin biopsy, lumbar puncture, enhanced MRI of the brachial plexus and MRI of the neuroaxis were normal. His pain was inadequately controlled with pregabalin but improved while on a weaning regimen of steroids. This case highlights the variety of possible symptoms associated with SARS-CoV-2 infection.

Regional migratory osteoporosis: case report of a patient with neuropathic pain

2009 ◽  
Vol 31 (10) ◽  
pp. 1375-1381 ◽  
Author(s):  
Esin Kartal ◽  
Ebru Sahin ◽  
Banu Dilek ◽  
Meltem Baydar ◽  
Metin Manisali ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Regional Migratory Osteoporosis

scholarly journals Spinal Cord Stimulation as a Treatment Option for Refractory Chemotherapy-Induced Peripheral Neuropathy: Case Report

2020 ◽  
Vol 39 (03) ◽  
pp. 228-231 ◽  
Author(s):  
Arthur Lopes ◽  
Kleber Duarte ◽  
Catarina Lins ◽  
Gabriel Kubota ◽  
Valquíria Silva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Spinal Cord ◽  
Neuropathic Pain ◽  
Case Report ◽  
Peripheral Neuropathy ◽  
Treatment Option ◽  
Spinal Cord Stimulation ◽  
Lower Limbs ◽  
Oncological Diseases ◽  
Good Treatment Option

AbstractColorectal cancer is one of the most common oncological diseases. Chemotherapy is usually recommended as an adjuvant treatment for stage-II, -III, and -IV tumors. Approximately 10% of the patients develop neuropathic pain after chemotherapy, and they may remain refractory despite the administration of drugs that are commonly used to treat neuropathic pain. Spinal cord stimulation is a good treatment option for neuropathic pain of the lower limbs, and it should be trialed in patients with chemotherapy-induced peripheral neuropathy. We report the case of a patient with oxaliplatin-induced neuropathy and neuropathic pain refractory to oral medication who was successfully treated by spinal cord stimulation.

Whole‐body reversible neuropathic pain associated with right parieto‐temporal operculum single inflammatory lesion in a patient with multiple sclerosis: A case report

2019 ◽  
Vol 23 (10) ◽  
pp. 1763-1766 ◽  
Author(s):  
Louis Poncet‐Megemont ◽  
Radhouane Dallel ◽  
Carine Chassain ◽  
Antoine Perrey ◽  
Sophie Mathais ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neuropathic Pain ◽  
Case Report ◽  
Inflammatory Lesion ◽  
Whole Body

Continuous Subcutaneous Infusion of Ketorolac in Cancer Neuropathic Pain Unresponsive to Opioid and Adjuvant Drugs. A Case Report

1996 ◽  
Vol 82 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Carla Ripamonti ◽  
Chiara Ticozzi ◽  
Ernesto Zecca ◽  
Carlos H. Rodriguez ◽  
Franco De Conno
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Side Effects ◽  
Cancer Patient ◽  
Cancer Pain ◽  
Antidepressant Drugs ◽  
Analgesic Efficacy ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion ◽  
Nonopioid Analgesic

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

Sign in / Sign up

Export Citation Format

Share Document